查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球药物发现市场评估：依药物类型、原产地、技术、最终使用者、地区、机会、预测（2017-2031）
市场调查报告书
商品编码
1408033

全球药物发现市场评估：依药物类型、原产地、技术、最终使用者、地区、机会、预测（2017-2031）

Global Drug Discovery Market Assessment, By Drug Type, By Source, By Technology, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 218 Pages | 商品交期: 3-5个工作天内

价格

全球药物发现市场规模预计到 2023 年将达到 682.4 亿美元，到 2031 年将达到 1541.2 亿美元，2024-2031 年预测期间复合年增长率为 10.72%。我是。 市场成长受到多种因素的推动，例如各种慢性病的流行、医疗保健支出的增加、某些常见药物的专利到期、人工智慧解决方案的采用以及公共和私营部门对生物医学研究的投资增加。

由于人口老化的增加，市场显示出更强劲的成长。 出生率下降、医疗设施增加导致预期寿命延长，以及世界各地针对老龄化人口的大量治疗选择，这些都是帮助人们延长寿命的因素。 然而，这进一步加速了老年人与年龄相关的疾病和慢性疾病的发生。 与此类模式竞争需要药物发现的创新和研发。 此外，每个国家都有法规负责确保和维持各个阶段药品的品质和标准，以检查批准药品的安全性和有效性，并改善人民的健康。

COVID-19 大流行加速了护理流动，导致各国医疗保健支出增加。 由于研究、药物开发和製造流程支出的增加，全球药物发现市场的医疗保健成本不断上升。 药物发现是一个昂贵、复杂且微妙的过程，由于药物研发的成本和风险，需要政府和製药公司的资助。 医疗保健支出可以带来更好的健康机会，进一步加强一个国家的医疗保健系统，并扩大全球药物发现市场。

慢性病流行

慢性病的流行是市场的主要驱动力。 据世界卫生组织称，包括心血管疾病、癌症、糖尿病和呼吸系统疾病在内的慢性疾病每年导致全球 4,100 万人死亡。 它影响所有年龄层的人，无论地区或国家。 不健康的饮食、久坐的生活方式、吸烟和酗酒是导致发展中国家和已开发国家慢性病的主要危险因子。 患病率的增加进一步推动了对新药发现的需求。 为了实现更健康的未来的目标，製药公司正在加速研发以发现新药。 新药的发现涉及治疗新的、慢性的和无法治疗的疾病的症状以及解决抗药性问题。 随着预期寿命的延长，人们变得更容易感染这些疾病，从而导致全球药物发现市场不断增长。

增加药物发现投资

支持药品生产，无论是小分子药物、蛋白质生物製剂、疫苗或体内诊断，都需要大量的公共和私人投资。 这些组织的投资正在为全球药物发现市场注入活力，帮助实现全球健康目标。 随着慢性病和新疾病的增加，需要开发和发现新药物来解决不断增长的人口的健康问题。 为了满足这项需求，美国、欧洲和亚太地区的许多生技公司正在大力投资药物发现。

政府措施

药物发现是一个耗时且成本高昂的过程，其各个製造步骤都需要政府的资金和支持。 各国政府花费数十亿美元用于药物发现研究和开发。 这笔支出涵盖各种活动，包括新药的发现和测试、技术创新的开发以及用于安全监测目的的临床试验。 各国政府推出了一系列措施、政策和计划来支持市场。

生物製品的需求不断增加

全球药物发现市场对生物药物的需求正在快速成长。 生物製品类别正在获得发展势头，因为它具有治疗被认为无法治疗或难以治疗的疾病的巨大潜力。 生物药物具有治疗目标疾病较专一且不易与其他药物反应的特性。 因此，服用多种药物的患者的安全性可以得到保证。 这些特性导致对生物製剂的需求迅速增加，包括日本、英国、印度、中国、美国和瑞典在内的许多国家正在开发复杂的生物製剂生产设施，以满足这种不断增长的需求。 。

本报告研究和分析了全球药物发现市场，提供市场规模和预测、市场动态以及主要参与者的现状和前景。

目录

第一章研究方法

第 2 章专案范围与定义

第三章全球药物发现市场的未来展望

第 4 章执行摘要

第五章全球药物发现市场展望（2017-2031）

  • 市场规模与预测
    • 金额
    • 数量
  • 依药物类型
    • 小分子
    • 生物製品
  • 按来源地
    • 自然
    • 合成
  • 按技术
    • 组合化学
    • 高通量筛选
    • 奈米技术
    • 药物基因组学
    • 其他技术
  • 按最终用户
    • 製药公司
    • 合约研究组织
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 南美洲
    • 亚太地区
    • 中东/非洲
  • 市占率：依公司划分（2023 年）

第 6 章全球药物发现市场前景：按地区划分（2017-2031 年）

  • 北美
    • 市场规模与预测
    • 依药物类型
    • 按来源地
    • 按技术
    • 按最终用户
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 英国
    • 俄罗斯
    • 荷兰
    • 西班牙
    • 土耳其
    • 波兰
  • 南美洲
    • 巴西
    • 阿根廷
  • 亚太地区
    • 印度
    • 中国
    • 日本
    • 澳大利亚
    • 越南
    • 韩国
    • 印尼
    • 菲律宾
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 南非

第 7 章市场地图（2023 年）

  • 依药物类型
  • 按来源地
  • 按技术
  • 按最终用户
  • 按地区

第八章宏观环境与产业结构

  • 需求与供给分析
  • 进出口分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 9 章市场动态

  • 生长促进因素
  • 抑製成长的因素（问题、限制因素）

第 10 章监理架构与创新

  • 临床试验
  • 专利情况
  • 监理机关的核准
  • 创新/新技术

第十一章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析（2023 年）
  • 併购/合资企业（如果适用）
  • SWOT 分析（5 家公司进入市场）
  • 专利分析（如果适用）

第十二章价格分析

第 13 章案例研究

第14章主要公司展望

  • Johnson & Johnson Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • Amgen, Inc.
  • Eli Lilly and Company
  • AbbVie Inc.
  • GlaxoSmithKline plc.
  • Bristol Myers Squibb
  • Sanofi Winthrop Industrie
  • AstraZeneca Plc.

第 15 章策略建议

第16章关于我们公司，免责声明

Product Code: MX10829

Global drug discovery market size was valued at USD 68.24 billion in 2023, which is expected to reach USD 154.12 billion in 2031, with a CAGR of 10.72% for the forecast period between 2024 and 2031F. Growth in global drug discovery market is driven by various factors such as rising prevalence of various chronic diseases, increasing healthcare expenditure, patent expiration of certain popular drugs, adoption of AI solutions, and increasing investments in private and public sector in the biomedical research.

The global drug discovery market is further undergoing robust growth due to an increase in the elderly population. Decrease in fertility rates, increase in life expectancy due to an increase in healthcare facilities, and vast treatment options available worldwide for the elderly population are the factors helping people to live longer. However, it has further accelerated age-related modalities and chronic diseases among the population. To combat these modalities, innovation and research & development in drug discovery are needed. Moreover, each country has its own set of regulations that are responsible to check the safety and efficacy of the approved drug to ensure and maintain the quality and standard of the drug at every step to improve the health of the population.

The COVID-19 pandemic has accelerated the movement of care resulting in increased healthcare expenditure across different countries. The increased healthcare expenditure has surged in global drug discovery market due to increased spending on research, drug development, and manufacturing process. Drug discovery is an expensive, complex, and sensitive process that requires funding from the government and pharmaceutical industry, due to the costs and risks associated with pharmaceutical R&D. Healthcare spending results in better provision of health opportunities that further strengthens the healthcare system of a country and simultaneously leads to the growth of global drug discovery market.

Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases is a major driving factor for the global drug discovery market. According to WHO, chronic diseases including cardiovascular diseases, cancer, diabetes, and respiratory illnesses are responsible for 41 million deaths every year at global level. It affects people of all age groups, irrespective of their region and countries. Unhealthy diet, sedentary lifestyle, tobacco use, and alcohol abuse are the leading risk factors for the rising chronic diseases in developing as well as developed countries. The increasing prevalence is further propelling the demand for new drug discoveries. To achieve the goal of a healthier future, pharmaceutical companies are accelerating research and development for discovering new medicines. Drug discoveries are required to treat symptoms of new diseases, chronic diseases, untreatable diseases, and to solve the issue of drug resistance. As life expectancy is increasing, people are more prone to getting exposed to these diseases, resulting in growth of global drug discovery market.

Increased Investments in Drug discovery

Significant public and private investments are needed to support the manufacturing of drugs, whether they are small molecule drugs, protein-based biologic drugs, vaccines, or in vivo diagnostics. These investments by the organizations is thriving the global drug discovery market to meet the global healthcare goals. With increase in chronic diseases and new diseases encounters, the need for developing and discovering new drugs to tackle the health issues of the growing population is the need of the hour. To meet this demand, many biotech companies in USA, Europe, and APAC have raised big investments in drug discoveries.

For instance, in September 2023, Generate Biomedicines raised USD 273 million in a Series C round to advance its generative AI pipeline of preclinical and clinical protein therapeutics. In the same month September 2023, Grit Biotechnology raised USD 60 million in a Series B round. Grit Biotechnology has its specialization in the field of tumor immunotherapy, and this investment will further support its tumor-infiltrating lymphocyte (TIL) pipeline development in the future. Hence, these investments in the drug developing process are expected to accelerate the global drug discovery market.

Government Initiatives

Drug discovery is a time consuming and expensive process and requires funds and support from the government on its various manufacturing steps. The Government has devoted billions for drug discovery R&D. The expenditure has covered a variety of activities such as discovering and testing new drugs, developing innovations, and clinical testing for safety-monitoring purpose. Government has launched many initiatives, policies, and programs to help and support global drug discovery market. For instance, according to an article published by US Government Accountability Office (GAO) on September 2023, The National Institutes of Health (NIH) has identified many viral families that have the potential to cause future pandemics. To combat these viral diseases there is a need to develop antiviral drugs. GAO has identified some technologies like artificial intelligence to speed up antiviral drug development process. In 2022, the White House issued the National Biodefense Strategy and Implementation Plan to support this agenda of antiviral drugs development.

Growing Demand for Biologics

There has been a notable surge in demand for biologics in the global drug discovery market. The category of Biologics is gaining momentum due to its huge potential to treat diseases, which are considered untreatable or difficult to treat. Biologics have attributes that makes them more specific to treat the targeted disease and are less likely to react with other drugs. Hence, they ensure safety of the patients who are taking multiple drugs. These attributes have resulted in an upsurge in demand for biologics and many countries, including Japan, the United Kingdom, India, China, the United States, and Sweden, beginning to develop complex biomanufacturing facilities to meet this rising demand. Major pharmaceutical corporations are entering the biologics space, for instance, in September 2023, Takeda Pharmaceuticals, Inc. got approval from Center for Biologics Evaluation and Research (CBER) for biologics named ADZYNMA, which is indicated for prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).

Use of AI in Drug Discovery

Drug development is a long, complex, and uncertain process that takes an average of 10-12 years to develop. The pharmaceutical industry is trying to create a fast and effective solution for drug development, and hence, companies are applying various computational methods to reach that goal. A novel technology called computer-aided drug design, or CADD, is used in the drug discovery process to find and develop a possible lead. Molecular modelling, molecular design, rational drug design and computational chemistry are all part of CADD. The use of AI can simplify and facilitate drug design by filtering datasets available. With the use of healthcare related data available in the records along with latest innovation in AI and Machine learning, it is possible to analyze the data and use it for faster and accurate outcomes. Thus, we can say that use of AI in drug discovery is further accelerating the global drug discovery market.

Many companies are using AI in their drug development process, for instance, on November 21, 2023, Genentech, a member of the Roche Group announced a multi-year strategic research collaboration with NVIDIA to use artificial intelligence (AI) to speed up drug discovery and development. NVIDIA and Genentech collaboration will help Genentech's AI/ML teams, to leverage AI and ML foundational models across numerous research areas including diverse therapeutic modalities as well as will help in gaining new insights, promoting growth in the global drug discovery market.

Future Market Scenario

Global drug discovery market is expected to grow in the coming years, due to multiple factors. Primarily, the increasing global aging population has led to a higher incidence of chronic illnesses such as cardiovascular diseases, cancer, diabetes, respiratory illness, and many more. Additionally, growth in the development of biosimilars and increased use of AI by the drugs manufacturing companies is further propelling the growth in the global drug discovery market. Other important driving factors are governmental support, policies, increase in healthcare expenditure and pharmaceutical regulatory agencies and organizations. The regulatory bodies maintain the safety and efficacy of the newly approved drug by thoroughly examining the drug manufacturing process. Collaborative ventures involving pharmaceutical companies, research institutions, and biotechnology firms have spurred innovation.

Key Players Landscape and Outlook

In the drug discovery market, companies progressively establish strategic partnerships and distribution agreements, which plays a pivotal role in market expansion. These alliances empower firms to harness each other's strengths, gain access to new markets and technologies, and pool resources for research and development endeavors. Distribution agreements enable companies to broaden their market presence at an international level. These collaborative initiatives promote innovation, expedite product development, and contribute to robust growth in the drug discovery market. In September 2023, Ono Pharmaceutical Co., Ltd., a Japanese firm announced that it has entered into a drug discovery collaboration agreement with Adimab, LLC., which is a global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies. The collaboration aims to discover and develop innovative antibody drugs in the oncology field.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Future Outlook of Global Drug Discovery Market

4. Executive Summary

5. Global Drug Discovery Market Outlook, 2017-2031F

  • 5.1. Market Size & Forecast
    • 5.1.1. Value
    • 5.1.2. Volume
  • 5.2. By Drug Type
    • 5.2.1. Small Molecules
    • 5.2.2. Biologics
  • 5.3. By Source
    • 5.3.1. Natural
    • 5.3.2. Synthetic
  • 5.4. By Technology
    • 5.4.1. Combinatorial chemistry
    • 5.4.2. High-throughput screening
    • 5.4.3. Nanotechnology
    • 5.4.4. Pharmacogenomics
    • 5.4.5. Other Technologies
  • 5.5. By End-user
    • 5.5.1. Pharmaceutical Companies
    • 5.5.2. Contract Research Organizations
    • 5.5.3. Others
  • 5.6. By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. South America
    • 5.6.4. Asia-Pacific
    • 5.6.5. Middle East and Africa
  • 5.7. By Company Market Share (%), 2023

6. Global Drug Discovery Market Outlook, By Region, 2017-2031F

  • 6.1. North America*
    • 6.1.1. Market Size & Forecast
      • 6.1.1.1. Value
      • 6.1.1.2. Volume
    • 6.1.2. By Drug Type
      • 6.1.2.1. Small Molecules
      • 6.1.2.2. Biologics
    • 6.1.3. By Source
      • 6.1.3.1. Natural
      • 6.1.3.2. Synthetic
    • 6.1.4. By Technology
      • 6.1.4.1. Combinatorial chemistry
      • 6.1.4.2. High-throughput screening
      • 6.1.4.3. Nanotechnology
      • 6.1.4.4. Pharmacogenomics
      • 6.1.4.5. Other Technologies
    • 6.1.5. By End-user
      • 6.1.5.1. Pharmaceutical Companies
      • 6.1.5.2. Contract Research Organizations
      • 6.1.5.3. Others
    • 6.1.6. United States*
      • 6.1.6.1. Market Size & Forecast
      • 6.1.6.1.1. Value
      • 6.1.6.1.2. Volume
      • 6.1.6.2. By Drug Type
      • 6.1.6.2.1. Small Molecules
      • 6.1.6.2.2. Biologics
      • 6.1.6.3. By Source
      • 6.1.6.3.1. Natural
      • 6.1.6.3.2. Synthetic
      • 6.1.6.4. By Technology
      • 6.1.6.4.1. Combinatorial chemistry
      • 6.1.6.4.2. High-throughput screening
      • 6.1.6.4.3. Nanotechnology
      • 6.1.6.4.4. Pharmacogenomics
      • 6.1.6.4.5. Other Technologies
      • 6.1.6.5. By End-user
      • 6.1.6.5.1. Pharmaceutical Companies
      • 6.1.6.5.2. Contract Research Organizations
      • 6.1.6.5.3. Others
    • 6.1.7. Canada
    • 6.1.8. Mexico

All segments will be provided for all regions and countries covered:

  • 6.2. Europe
    • 6.2.1 Germany
    • 6.2.2 France
    • 6.2.3 Italy
    • 6.2.4 United Kingdom
    • 6.2.5 Russia
    • 6.2.6 Netherlands
    • 6.2.7 Spain
    • 6.2.8 Turkey
    • 6.2.9 Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
  • 6.4. Asia Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2023

  • 7.1. By Drug Type
  • 7.2. By Source
  • 7.3. By Technology
  • 7.4. By End-user
  • 7.5. By Region

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis
  • 8.3. Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges and Restraints)

10. Regulatory Framework and Innovation

  • 10.1 Clinical Trials
  • 10.2 Patent Landscape
  • 10.3 Regulatory Approvals
  • 10.4 Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. Johnson & Johnson Inc.
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. F. Hoffmann-La Roche Ltd.
  • 14.3. Pfizer Inc.
  • 14.4. Novartis AG
  • 14.5. Merck & Co., Inc.
  • 14.6. Amgen, Inc.
  • 14.7. Eli Lilly and Company
  • 14.8. AbbVie Inc.
  • 14.9. GlaxoSmithKline plc.
  • 14.10. Bristol Myers Squibb
  • 14.11. Sanofi Winthrop Industrie
  • 14.12. AstraZeneca Plc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 3. Global Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 4. Global Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 5. Global Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 6. Global Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global Drug Discovery Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 10. North America Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 11. North America Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 12. North America Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 13. North America Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 14. North America Drug Discovery Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 17. United States Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 18. United States Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 19. United States Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 20. United States Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 21. Canada Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 23. Canada Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 24. Canada Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 25. Canada Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 26. Canada Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 27. Mexico Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 29. Mexico Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 30. Mexico Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 31. Mexico Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 32. Mexico Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 35. Europe Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 36. Europe Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 37. Europe Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 38. Europe Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 39. Europe Drug Discovery Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 42. Germany Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 43. Germany Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 44. Germany Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 45. Germany Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 46. France Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 48. France Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 49. France Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 50. France Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 51. France Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 52. Italy Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 54. Italy Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 55. Italy Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 56. Italy Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 57. Italy Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 58. United Kingdom Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 60. United Kingdom Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 61. United Kingdom Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 62. United Kingdom Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 63. United Kingdom Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 64. Russia Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 66. Russia Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 67. Russia Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 68. Russia Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 69. Russia Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 70. Netherlands Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 72. Netherlands Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 73. Netherlands Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 74. Netherlands Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 75. Netherlands Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 76. Spain Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 78. Spain Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 79. Spain Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 80. Spain Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 81. Spain Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 82. Turkey Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 84. Turkey Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 85. Turkey Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 86. Turkey Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 87. Turkey Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 88. Poland Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 90. Poland Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 91. Poland Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 92. Poland Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 93. Poland Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 94. South America Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 96. South America Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 97. South America Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 98. South America Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 99. South America Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 100. South America Drug Discovery Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 103. Brazil Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 104. Brazil Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 105. Brazil Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 106. Brazil Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 107. Argentina Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 109. Argentina Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 110. Argentina Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 111. Argentina Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 112. Argentina Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 113. Asia-Pacific Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 115. Asia-Pacific Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 116. Asia-Pacific Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 117. Asia-Pacific Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 118. Asia-Pacific Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 119. Asia-Pacific Drug Discovery Market Share (%), By Country, 2017-2031F
  • Figure 120. India Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 122. India Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 123. India Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 124. India Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 125. India Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 126. China Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 128. China Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 129. China Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 130. China Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 131. China Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 132. Japan Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 134. Japan Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 135. Japan Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 136. Japan Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 137. Japan Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 138. Australia Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 140. Australia Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 141. Australia Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 142. Australia Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 143. Australia Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 144. Vietnam Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 146. Vietnam Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 147. Vietnam Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 148. Vietnam Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 149. Vietnam Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 150. South Korea Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 152. South Korea Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 153. South Korea Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 154. South Korea Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 155. South Korea Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 156. Indonesia Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 158. Indonesia Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 159. Indonesia Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 160. Indonesia Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 161. Indonesia Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 162. Philippines Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 164. Philippines Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 165. Philippines Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 166. Philippines Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 167. Philippines Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 168. Middle East & Africa Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 170. Middle East & Africa Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 171. Middle East & Africa Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 172. Middle East & Africa Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 173. Middle East & Africa Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 174. Middle East & Africa Drug Discovery Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 177. Saudi Arabia Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 178. Saudi Arabia Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 179. Saudi Arabia Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 180. Saudi Arabia Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 181. UAE Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 183. UAE Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 184. UAE Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 185. UAE Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 186. UAE Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 187. South Africa Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 189. South Africa Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 190. South Africa Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 191. South Africa Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 192. South Africa Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 193. By Drug Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Source Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023